

Alfonso Ielasi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5258895/publications.pdf>

Version: 2024-02-01

216
papers

4,281
citations

147801

31
h-index

138484

58
g-index

251
all docs

251
docs citations

251
times ranked

4717
citing authors

#	ARTICLE	IF	CITATIONS
1	ST-Elevation Myocardial Infarction in Patients With COVID-19. <i>Circulation</i> , 2020, 141, 2113-2116.	1.6	376
2	Management and Long-Term Prognosis of Spontaneous Coronary Artery Dissection. <i>American Journal of Cardiology</i> , 2015, 116, 66-73.	1.6	230
3	Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 87-95.	2.9	170
4	Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2009, 11, 581-587.	7.1	143
5	Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1882-1893.	2.8	140
6	5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 595-601.	2.9	136
7	Outcomes After Transcatheter Aortic Valve Implantation With Both Edwards-SAPIEN and CoreValve Devices in a Single Center. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1110-1121.	2.9	124
8	A new technique for vascular access management in transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 784-793.	1.7	123
9	Mechanisms of Very Late Bioresorbable Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2330-2344.	2.8	117
10	Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: A propensity score-matched case-control study. <i>American Heart Journal</i> , 2012, 164, 910-917.	2.7	111
11	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2079-2088.	2.9	103
12	Incidence, Management, and Immediate- and Long-Term Outcomes After Iatrogenic Aortic Dissection During Diagnostic or Interventional Coronary Procedures. <i>Circulation</i> , 2015, 131, 2114-2119.	1.6	87
13	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006023.	3.9	80
14	Coronary chronic total occlusions. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 20-27.	1.7	71
15	Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 155-164.	2.9	66
16	Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1-14.	2.8	64
17	Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 743-750.	2.9	62
18	Balloon Versus Self-Expandable Valve for the Treatment of Bicuspid Aortic Valve Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008714.	3.9	62

#	ARTICLE	IF	CITATIONS
19	Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 416-422.	3.9	54
20	In-hospital and midterm clinical outcomes of rotational atherectomy followed by stent implantation: the ROTATE multicentre registry. <i>EuroIntervention</i> , 2016, 12, 1448-1456.	3.2	49
21	Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry). <i>EuroIntervention</i> , 2015, 11, 157-162.	3.2	46
22	Coronary artery aneurysms, insights from the international coronary artery aneurysm registry (CAAR). <i>International Journal of Cardiology</i> , 2020, 299, 49-55.	1.7	46
23	Clinical and Angiographic Outcomes After Percutaneous Recanalization of Chronic Total Saphenous Vein Graft Occlusion Using Modern Techniques. <i>American Journal of Cardiology</i> , 2010, 106, 1721-1727.	1.6	45
24	ROTational ATHERectomy in acute coronary syndrome: early and midterm outcomes from a multicentre registry. <i>EuroIntervention</i> , 2016, 12, 1457-1464.	3.2	43
25	Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. <i>EuroIntervention</i> , 2012, 7, 1275-1284.	3.2	43
26	Rotational atherectomy in very long lesions: Results for the ROTATE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E164-E172.	1.7	39
27	Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multicenter registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 881-889.	1.7	38
28	IntraVascular Lithotripsy for the Management of Undilatable Coronary StEnt: The SMILE Registry. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1555-1559.	0.8	37
29	Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. <i>American Journal of Cardiology</i> , 2015, 116, 705-710.	1.6	36
30	Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. <i>International Journal of Cardiology</i> , 2015, 199, 366-372.	1.7	34
31	Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003148.	3.9	33
32	First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1901-1903.	2.9	33
33	Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. <i>International Journal of Cardiology</i> , 2014, 173, 513-514.	1.7	32
34	Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). <i>International Journal of Cardiology</i> , 2016, 208, 40-45.	1.7	32
35	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1165-1178.	2.8	32
36	Unplanned Percutaneous Coronary Revascularization After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 198-207.	2.9	30

#	ARTICLE	IF	CITATIONS
37	Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 491-498.	3.9	29
38	Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 94-100.	1.5	29
39	Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1219-1226.	2.9	28
40	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. <i>International Journal of Cardiology</i> , 2013, 165, 444-447.	1.7	27
41	Complications Following Percutaneous Mitral Valve Repair. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 146.	2.4	27
42	Sealing spontaneous coronary artery dissection with bioresorbable vascular scaffold implantation: Data from the prospective "Registro Absorb Italiano" (RAI Registry). <i>International Journal of Cardiology</i> , 2016, 212, 44-46.	1.7	26
43	Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. <i>EuroIntervention</i> , 2013, 9, 809-816.	3.2	26
44	Impact of Residual Chronic Total Occlusion of Right Coronary Artery on the Long-term Outcome in Patients Treated for Unprotected Left Main Disease. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 154-160.	3.9	24
45	Defining a new standard for IVUS optimized drug eluting stent implantation: The PRAVIO study. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 348-356.	1.7	22
46	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1855-1864.	2.9	22
47	Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 350-357.	2.9	21
48	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	2.0	21
49	Quantitative Angiographic Assessment of Aortic Regurgitation after Transcatheter Aortic Valve Implantation among Three Balloon-Expandable Valves. <i>Global Heart</i> , 2021, 16, 20.	2.3	21
50	Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study. <i>EuroIntervention</i> , 2022, 17, e1397-e1406.	3.2	21
51	Current and future drug-eluting coronary stent technology. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 485-503.	1.5	20
52	Acute and long-term outcomes after polytetrafluoroethylene or pericardium covered stenting for grade 3 coronary artery perforations: Insights from G3-CAP registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1247-1255.	1.7	20
53	Intravascular lithotripsy in calcified coronary lesions: A real-world observational, European multicenter study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 225-235.	1.7	20
54	Optical coherence tomography, intravascular ultrasound or angiography guidance for distal left main coronary stenting. The ROCK cohort II study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 664-673.	1.7	20

#	ARTICLE	IF	CITATIONS
55	Comparison of Long-Term Clinical and Angiographic Outcomes Following Implantation of Bare Metal Stents and Drug-Eluting Stents in Aorto-Ostial Lesions. <i>American Journal of Cardiology</i> , 2011, 108, 1055-1060.	1.6	19
56	In-Hospital and 1-Year Outcomes of Rotational Atherectomy and Stent Implantation in Patients With Severely Calcified Unprotected Left Main Narrowings (from the Multicenter ROTATE Registry). <i>American Journal of Cardiology</i> , 2017, 119, 1331-1337.	1.6	19
57	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry. <i>International Journal of Cardiology</i> , 2021, 325, 109-114.	1.7	19
58	The impact of main branch restenosis on long term mortality following drug-eluting stent implantation in patients with <i>de novo</i> unprotected distal left main bifurcation coronary lesions: The Milan and Newâ€”Tokyo (MITO) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 341-348.	1.7	18
59	Coronary Left Main and Nonâ€”Left Main Bifurcation Angles: How are the Angles Modified by Different Bifurcation Stenting Techniques?. <i>Journal of Interventional Cardiology</i> , 2010, 23, 382-393.	1.2	17
60	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 249-256.	3.9	17
61	Everolimus-eluting stent versus bare-metal stent in elderly (>=75years) versus non-elderly (<75years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. <i>International Journal of Cardiology</i> , 2015, 179, 73-78.	1.7	17
62	Longâ€”term clinical outcomes following drug-eluting stent implantation for unprotected distal trifurcation left main disease: The Milanâ€”New Tokyo (MITO) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 530-538.	1.7	16
63	Coronary Sinus Reducer systemâ„¢: A new therapeutic option in refractory angina patients unsuitable for revascularization. <i>International Journal of Cardiology</i> , 2016, 209, 122-130.	1.7	16
64	Treatment of iatrogenic occlusive coronary dissections: a novel approach. <i>EuroIntervention</i> , 2011, 7, 106-111.	3.2	16
65	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULTImaster Italian multicenter all comers Stent registry). <i>International Journal of Cardiology</i> , 2018, 260, 36-41.	1.7	15
66	Transradial versus transfemoral ancillary approach in complex structural, coronary, and peripheral interventions. Results from the multicenter ancillary registry: A study of the Italian Radial Club. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 97-102.	1.7	15
67	Safety of FFR-guided revascularisation deferral in Anatomically prognostic disease (FACE): Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 270, 107-112.	1.7	15
68	Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 32-40.	4.0	15
69	Usefulness of Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 139, 22-27.	1.6	15
70	Safety and Efficacy of Myval Implantation in Patients with Severe Bicuspid Aortic Valve Stenosisâ€”A Multicenter Real-World Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 443.	2.4	14
71	Clinical outcomes of realâ€”world patients treated with an amphilimus polymerâ€”free stent versus new generation everolimusâ€”eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1168-1176.	1.7	13
72	â€œRota-Tripsyâ€” A Successful Combined Approach for the Treatment of a Long and Heavily Calcified Coronary Lesion. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 152-154.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the "more metallic cages" multicentre pilot experience. <i>EuroIntervention</i> , 2016, 11, e1589-e1595.	3.2	13
74	Registro Absorb Italiano (BVS-RAI): an investigators-owned and -directed, open, prospective registry of consecutive patients treated with the Absorb, BVS: study design. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 340-343.	0.8	12
75	Bioresorbable vascular scaffolds for small vessels coronary disease: The BVSsave registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 380-387.	1.7	12
76	SARS-CoV-2 Aiming for the Heart: A Multicenter Italian Perspective About Cardiovascular Issues in COVID-19. <i>Frontiers in Physiology</i> , 2020, 11, 571367.	2.8	12
77	Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol. <i>PLoS ONE</i> , 2021, 16, e0255263.	2.5	12
78	Safety and efficacy of coronary sinus narrowing in chronic refractory angina: Insights from the RESOURCE study. <i>International Journal of Cardiology</i> , 2021, 337, 29-37.	1.7	12
79	An Update on New Generation Transcatheter Aortic Valves and Delivery Systems. <i>Journal of Clinical Medicine</i> , 2022, 11, 499.	2.4	12
80	A high dose of adenosine to induce transient asystole for valvuloplasty in patients undergoing transcatheter aortic valve implantation (TAVI): is it a valid alternative to rapid pacing? A prospective pilot study. <i>Journal of Invasive Cardiology</i> , 2011, 23, 467-71.	0.4	12
81	Clinical Comparison of a Novel Balloon-Expandable Versus a Self-Expanding Transcatheter Heart Valve for the Treatment of Patients with Severe Aortic Valve Stenosis: The EVAL Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 959.	2.4	12
82	Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1543-1554.	2.9	12
83	Bioresorbable scaffolds and drug-eluting balloons for the management of spontaneous coronary artery dissections. <i>Journal of Thoracic Disease</i> , 2016, 8, E1328-E1330.	1.4	11
84	Current results and remaining challenges of trans-catheter aortic valve replacement expansion in intermediate and low risk patients. <i>IJC Heart and Vasculature</i> , 2019, 23, 100375.	1.1	11
85	Sirolimus-Eluting Magnesium Resorbable Scaffold Implantation in Patients with Acute Myocardial Infarction. <i>Cardiology</i> , 2019, 142, 93-96.	1.4	11
86	"RotaTripsy" for Severe Calcified Coronary Artery Lesions: Insights From a Real-World Multicenter Cohort. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 78-81.	0.8	11
87	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 220-227.	0.8	10
88	Resultados a muy largo plazo tras la implantación de stents liberadores de fármacos en la estenosis de arteria coronaria principal izquierda no protegida: experiencia de un centro. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 24-33.	1.2	10
89	Current and new-generation transcatheter aortic valve devices: an update on emerging technologies. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1393-1405.	1.5	10
90	Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	1.6	10

#	ARTICLE	IF	CITATIONS
91	Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?. Journal of Thoracic Disease, 2017, 9, S969-S978.	1.4	10
92	A HYbrid APproach Evaluating a DRug-Coated Balloon in Combination With a New-Generation Drug-Eluting Stent in the Treatment of De Novo Diffuse Coronary Artery Disease: The HYPER Pilot Study. Cardiovascular Revascularization Medicine, 2021, 28, 14-19.	0.8	10
93	Clinical Outcomes Following Protected Carotid Artery Stenting in Symptomatic and Asymptomatic Patients. Journal of Endovascular Therapy, 2010, 17, 298-307.	1.5	9
94	Resolute italian study in all comers. Catheterization and Cardiovascular Interventions, 2012, 79, 567-574.	1.7	9
95	No more metallic cages: An attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel. International Journal of Cardiology, 2014, 172, 618-619.	1.7	9
96	Very late bioresorbable vascular scaffold thrombosis due to late device recoil. International Journal of Cardiology, 2015, 189, 132-133.	1.7	9
97	A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY study. Catheterization and Cardiovascular Interventions, 2017, 89, 1129-1138.	1.7	9
98	Hybrid coronary revascularization versus percutaneous strategies in left main stenosis: a propensity match study. Journal of Cardiovascular Medicine, 2018, 19, 253-260.	1.5	9
99	Percutaneous mechanical circulatory support from the collaborative multicenter Mechanical Unusual Support in TAVI (MUST) Registry. Catheterization and Cardiovascular Interventions, 2021, 98, E862-E869.	1.7	9
100	Rationale and design of a multicenter, international and collaborative Coronary Artery Aneurysm Registry (CAAR). Clinical Cardiology, 2017, 40, 580-585.	1.8	8
101	Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis. Clinical Research in Cardiology, 2021, 110, 667-675.	3.3	8
102	Incidence, Management, Immediate and Long-Term Outcome of Guidewire and Device Related Grade III Coronary Perforations (from G3CAP - Cardiogroup VI Registry). American Journal of Cardiology, 2021, 143, 37-45.	1.6	8
103	Stent Thrombosis and Duration of Dual Antiplatelet Therapy. Current Pharmaceutical Design, 2010, 16, 4052-4063.	1.9	7
104	Directional atherectomy of a heavy calcified axillary artery stenosis inducing critical hand ischemia. Cardiovascular Intervention and Therapeutics, 2013, 28, 300-302.	2.3	7
105	Pulmonary embolism with migrating thrombus through patent foramen ovale: A case for a mixed pharmacological and percutaneous management. Journal of Cardiology Cases, 2019, 19, 19-21.	0.5	7
106	Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2021, 6, 936.	6.1	7
107	Management and Outcome of Failed Percutaneous Edge-to-Edge Mitral Valve Plasty. JACC: Cardiovascular Interventions, 2022, 15, 411-422.	2.9	7
108	Prolonged Double Antiplatelet Therapy in a Cohort of De Novo Diabetic Patients Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 1395-1401.	1.6	6

#	ARTICLE	IF	CITATIONS
109	Successful management of a huge thrombus in coronary aneurysmatic dilatation after failed mechanical thrombectomy during acute myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 80-81.	1.5	6
110	Current and future perspectives on drug-eluting bioresorbable coronary scaffolds. <i>Future Cardiology</i> , 2014, 10, 409-420.	1.2	6
111	Impact of renal dysfunction on long-term mortality in patients with unprotected left main disease: Milan and New-Tokyo (MITO) Registry. <i>International Journal of Cardiology</i> , 2014, 177, 1131-1133.	1.7	6
112	Guide-catheter extension system facilitated multiple bioresorbable vascular scaffolds (ABSORB®) delivery in a very long and resistant coronary artery lesion. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 117-120.	0.8	6
113	Outcomes following primary percutaneous coronary intervention for unprotected left main-related ST-segment elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 163-169.	1.5	6
114	Sustained Reduction of Tricuspid Regurgitation After Percutaneous Repair With the MitraClip System in a Patient With a Dual Chamber Pacemaker. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e147-e149.	2.9	6
115	Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry). <i>International Journal of Cardiology</i> , 2018, 258, 50-54.	1.7	6
116	Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-year follow-up of a propensity score matching comparison (the BIOROLVE-ISR Study). <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 668-677.	1.7	6
117	Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E115-E124.	1.7	6
118	Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov) https://doi.org/10.1007/s10086-019-01607-0	1.7	6
119	One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study). <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 700-704.	0.8	6
120	Transcatheter Valve-in-Valve Implantation With a Novel Balloon-Expandable Device in Patients With Bioprosthetic Heart Valve Failure: A Case Series. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 98-101.	0.8	6
121	Outcome of Coronary Ostial Stenting to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009017.	3.9	6
122	Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 411-420.	1.7	6
123	Broken heart syndrome: tako-tsubo cardiomyopathy. <i>Cmaj</i> , 2009, 180, 1033-1034.	2.0	5
124	Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. <i>Medical Devices: Evidence and Research</i> , 2015, 8, 317.	0.8	5
125	Late Structural Discontinuity as a Possible Cause of Very Late Everolimus-Eluting Bioresorbable Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e171-e172.	2.9	5
126	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 972-979.	1.7	5

#	ARTICLE	IF	CITATIONS
127	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULTimaster Italian multicenter all comerS) Tj ETQq1 1 0.784314 rgBT /Over	1.0	3
128	Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020, 38, 575-588.	2.2	5
129	The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance. <i>Cardiovascular Revascularization Medicine</i> , 2022, 39, 106-113.	0.8	5
130	One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI) Tj ETQq0 0 0 rgBT /Overlock 10 TF	3.2	5
131	Dual antiplatelet therapy strategies and clinical outcomes in patients treated with polymer-free biolimus A9-coated stents. <i>EuroIntervention</i> , 2020, 15, e1358-e1365.	3.2	5
132	Back to the future: the role of DCB for the treatment of coronary bifurcation. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 1421.	1.4	5
133	SPECIES VARIATION IN ANTIBODY RESPONSE. <i>The Australian Journal of Experimental Biology and Medical Science</i> , 1969, 47, 689-699.	0.7	4
134	Kissing drug-eluting balloons for the treatment of unprotected distal left main bifurcation drug-eluting stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 347-349.	0.8	4
135	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULTimaster Italian multicenter all comerS Stent rEgistry). <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 255-265.	1.7	4
136	Impact of Absorb bioresorbable scaffold implantation technique on post-procedural quantitative coronary angiographic endpoints in ST-elevation myocardial infarction: a sub-analysis of the BVS STEMI STRATEGY-IT study. <i>EuroIntervention</i> , 2019, 15, 108-115.	3.2	4
137	Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry. <i>International Journal of Cardiology</i> , 2022, 349, 31-38.	1.7	4
138	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 24-33.	0.6	3
139	Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 522-529.	1.7	3
140	Multimodal Imaging of Post-Stenting Mycotic Coronary Pseudoaneurysm Complicated by Device Fracture and Myocardial Abscess. <i>JACC: Case Reports</i> , 2020, 2, 1667-1670.	0.6	3
141	Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 66-73.	0.8	3
142	Assessing the Impact of Transcatheter Aortic Valve Implantation on Cardiac Catheterisation: A Multicentric Study. <i>Heart Lung and Circulation</i> , 2021, 30, 1397-1405.	0.4	3
143	Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient. <i>Journal of Atrial Fibrillation</i> , 2016, 9, 1509.	0.5	3
144	The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 2926.	2.4	3

#	ARTICLE	IF	CITATIONS
145	Static and Dynamic Predictors of Adverse Events in Patients with Intermediate Cardiopulmonary Capacity Referred for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 85-89.	0.6	2
146	Scimitar syndrome. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 176-177.	1.5	2
147	TCT-430 Ancillary radial versus femoral/brachial approach to reduce vascular complications in complex coronary, peripheral and structural interventions. Preliminary results of a study from the Italian Radial Club. <i>Journal of the American College of Cardiology</i> , 2015, 66, B175-B176.	2.8	2
148	Impact and natural history of postprocedural aortic regurgitation on early and midterm mortality following transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 286-295.	1.5	2
149	TCT-425 Bioresorbable vascular scaffold technology for small vessel coronary artery disease: results from the Italian multicenter RAI Registry. <i>Journal of the American College of Cardiology</i> , 2016, 68, B171-B172.	2.8	2
150	An unusual case of cardiogenic shock late following surgical aortic valve replacement. <i>Journal of Cardiology Cases</i> , 2016, 13, 162-164.	0.5	2
151	Management of diabetic patients hospitalized for acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 572-579.	1.5	2
152	TCT CONNECT-7 Everolimus-Eluting Stent Versus Bare-Metal Stent in ST-Segment Elevation Myocardial Infarction: 10-Year Follow-Up of the Multicenter Randomized Controlled Examination Trial. <i>Journal of the American College of Cardiology</i> , 2020, 76, B4.	2.8	2
153	Dual antiplatelet therapy prolongation in high-risk patients with prior myocardial infarction: insights from the post-PCI registry. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 603-609.	1.5	2
154	MyVal and Mini-Chimney Stenting to Prevent Coronary Obstruction During Full Root Stent-Less Aortic Valve-In-Valve Procedure. <i>Cardiovascular Revascularization Medicine</i> , 2021, 22, 122-123.	0.8	2
155	Results of paclitaxel-drug-coated balloons (Pantera Lux) for coronary in-stent restenosis: Italian experience from REGistry of Paclitaxel Eluting Balloon in ISR study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 469-477.	1.5	2
156	Snaring the Transcatheter Heart Valve Delivery System During Aortic Valve Replacement: When and Why. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 81-84.	0.8	2
157	Latest generation stents: is it time to revive the bioresorbable scaffold?. <i>Minerva Cardioangiologica</i> , 2020, 68, 415-435.	1.2	2
158	Bioresorbable vascular scaffold implantation for recurrent in-stent restenosis: an option in case of multiple failures?. <i>EuroIntervention</i> , 2014, 10, 337-337.	3.2	2
159	“Full plastic jacket” 18-month follow-up after implantation of multiple overlapping bioresorbable vascular scaffolds. <i>EuroIntervention</i> , 2015, 11, e1-e1.	3.2	2
160	The impact of the use of bioresorbable vascular scaffolds and drug-coated balloons in coronary bifurcation lesions. <i>Egyptian Heart Journal</i> , 2019, 71, 31.	1.2	2
161	“Shock-Pella” Combined management of an undilatable ostial left circumflex stenosis in a complex high-risk interventional procedure patient. <i>Cardiology Journal</i> , 2020, 27, 427-428.	1.2	2
162	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis treated with transcatheter valve replacement: insights from the BEAT international collaborative registry. <i>European Heart Journal</i> , 2020, 41, .	2.2	2

#	ARTICLE	IF	CITATIONS
163	Trans-Catheter Valve-in-Valve Implantation for the Treatment of Aortic Bioprosthetic Valve Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 344.	2.4	2
164	Safety and efficacy of systematic lesion preparation with a novel generation scoring balloon in complex percutaneous interventions: results from a prospective registry. <i>Minerva Cardiology and Angiology</i> , 2023, 70, .	0.7	2
165	Malignant ST segment elevation. <i>European Heart Journal</i> , 2008, 29, 2448-2448.	2.2	1
166	Anomalous left coronary artery origin from the pulmonary artery: an unusual late presentation of Blandin-Garland-White syndrome. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 719-721.	1.5	1
167	Sandwich Stenting to Treat an Ostial Left Main Narrowing Following Transcatheter Aortic Valve Implantation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 1220-1222.	0.6	1
168	TCT-517 Long term clinical outcome following Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-stent Restenosis: a Multicenter Italian Experience. <i>Journal of the American College of Cardiology</i> , 2015, 66, B211.	2.8	1
169	A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, S4-S9.	0.8	1
170	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 743-745.	2.9	1
171	Final shape of biovascular scaffolds and clinical outcome. Results from a multicenter all-comers study with intravascular imaging. <i>International Journal of Cardiology</i> , 2017, 228, 209-213.	1.7	1
172	First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis. <i>Coronary Artery Disease</i> , 2017, 28, 437-439.	0.7	1
173	Bioresorbable Vascular Scaffolds in In-Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 220-221.	2.9	1
174	One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 404-410.	1.7	1
175	ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry. <i>Cardiovascular Revascularization Medicine</i> , 2021, 30, 1-8.	0.8	1
176	Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E248-E256.	1.7	1
177	Type A aortic dissection after transcatheter aortic valve replacement: is a surgical approach always needed?. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, e29-e31.	1.5	1
178	Tools & Techniques: Left main coronary artery percutaneous coronary intervention. <i>EuroIntervention</i> , 2011, 6, 1020-1021.	3.2	1
179	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 278-280.	1.5	1
180	Impact of COVID-19 pandemic on in-hospital outcomes for patients with acute coronary syndrome: a propensity-weighted, multicentre study. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	1

#	ARTICLE	IF	CITATIONS
181	Reply on anomalous left coronary artery origin from the pulmonary artery (ALCAPA): an unusual late presentation of Blandâ€™Garlandâ€™White syndrome. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 556.	1.5	0
182	039â€™...Outcomes following unprotected left main stenting with first vs second generation drug-eluting stents: the Milan experience. <i>Heart</i> , 2012, 98, A24.2-A24.	2.9	0
183	TCT-370 Outcomes According to Sex Following Unprotected Left Main Stenting With Drug-Eluting Stents: The Milan Experience. <i>Journal of the American College of Cardiology</i> , 2012, 60, B106.	2.8	0
184	TCT-701 Two Year Outcomes Following Unprotected Left Main Stenting with First- vs. New-Generation Drug-Eluting Stents: The FINE Registry. <i>Journal of the American College of Cardiology</i> , 2012, 60, B204.	2.8	0
185	TCT-709 Predictors of Main Branch Restenosis Following Drug-eluting Stent Implantation in Patients with De Novo Unprotected Distal Left Main Bifurcation Coronary Lesions: The Milan and New-Tokyo (MITO) Registry. <i>Journal of the American College of Cardiology</i> , 2012, 60, B206.	2.8	0
186	AS-170 Outcomes Following Unprotected Left Main Stenting with Newer Generation Drug-Eluting Stents: The Milan Experience. <i>American Journal of Cardiology</i> , 2012, 109, S85.	1.6	0
187	TCT-812 The Impact of Renal Function on Long-term Mortality in Unprotected Left Main Disease, Milan and New-Tokyo Registry. <i>Journal of the American College of Cardiology</i> , 2013, 62, B246.	2.8	0
188	Impact of bifurcation technique on long-term clinical outcomes in 976 patients with distal unprotected left main coronary artery stenosis treated with drug-eluting stents; Milan and new-Tokyo registry. <i>European Heart Journal</i> , 2013, 34, P3998-P3998.	2.2	0
189	Long-term survival in patients undergoing drug-eluting stent PCI of the unprotected left main coronary artery according to renal function; Milan and New-Tokyo (MITO) registry. <i>European Heart Journal</i> , 2013, 34, P4813-P4813.	2.2	0
190	TCT-609 Comparison of one year outcomes in real world patients treated with a polymer free amphimus eluting coronary stent versus second generation everolimus eluting stents. <i>Journal of the American College of Cardiology</i> , 2014, 64, B178.	2.8	0
191	TCT-538 Clinical outcomes following percutaneous coronary intervention with Absorb BVS in patients with distal coronary artery disease. Results from the Italian RAI multicenter registry. <i>Journal of the American College of Cardiology</i> , 2015, 66, B220.	2.8	0
192	TCT-417 Bioresorbable vascular scaffold in chronic total coronary artery occlusions: results from the RAI registry. <i>Journal of the American College of Cardiology</i> , 2016, 68, B168-B169.	2.8	0
193	CRT-100.78 A Hybrid Strategy With Bioresorbable Vascular Scaffolds And Drug Eluting Stents For Treating Complex Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, S25.	2.9	0
194	TCTAP A-059 Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary in Stent Restenosis: Long-term Clinical Outcomes of a Multicenter Italian Experience. <i>Journal of the American College of Cardiology</i> , 2017, 69, S31.	2.8	0
195	TCTAP C-080 First-in-man Demonstration of Complete Bioresorbable Vascular Scaffold Resorption After Treatment of In-stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2017, 69, S169-S170.	2.8	0
196	Bioresorbable coronary scaffolds in 2017. <i>Journal of Thoracic Disease</i> , 2017, 9, S886-S886.	1.4	0
197	TCT-353 Acute and mid-term performance of Magmaris Bioresorbable Scaffold implantation in complex lesions: a multicenter experience.. <i>Journal of the American College of Cardiology</i> , 2018, 72, B144.	2.8	0
198	P6378A polymer-free biolimus-coated stent for the management of real-world high bleeding risk patients with coronary artery disease. <i>European Heart Journal</i> , 2018, 39, .	2.2	0

#	ARTICLE	IF	CITATIONS
199	TCT-704 Feasibility of overlapped Magnesium-made bioresorbable scaffold implantation in long lesions: results from the multicenter italian registry (MAGIC). <i>Journal of the American College of Cardiology</i> , 2018, 72, B281-B282.	2.8	0
200	P2820 Contemporary indications, dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent: the all-comers FREEDOM registry. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
201	P2794 Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free biolimus A9-coated stent: insights from the all-comers FREEDOM registry. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
202	P2801 Hard events after orsiro sirolimus-eluting stent (HEROES) in STEMI: a multicenter registry. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
203	P5531 A systematic follow-up strategy after percutaneous coronary intervention based on patient risk profile: the prospective POST-PCI registry. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
204	Editorial: Percutaneous Mitral Valve Interventions (Repair): Current Indications and Future Perspectives. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 581109.	2.4	0
205	Successful Percutaneous Closure of an Iatrogenic Ventricular Septal Defect Following TAVR With the ACURATE neo2. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e173-e176.	2.9	0
206	Percutaneous Unprotected Left Main Coronary Artery Interventions – Updated Results and Current Recommendations. <i>Interventional Cardiology Review</i> , 2011, 6, 44.	1.6	0
207	The impact of the 3-year ABSORB II trial results on my clinical practice: an Italian survey. <i>Journal of Thoracic Disease</i> , 2017, 9, S898-S902.	1.4	0
208	Recurrent and life-threatening strokes after pacemaker implantation in a patient affected by concealed superior sinus venosus atrial septal defect. <i>Cardiology Journal</i> , 2019, 26, 300-301.	1.2	0
209	Intracoronary lithoplasty-facilitated expansion of an undilatable intra-stent lesion. <i>AsiaIntervention</i> , 2020, 6, 58-59.	0.4	0
210	Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 825-828.	1.5	0
211	The diabetic dilemma: which drug-eluting stent works best?. <i>Minerva Cardioangiologica</i> , 2014, 62, 39-57.	1.2	0
212	CRT-700.31 Implantation of Contemporary Transcatheter Aortic Valves in Small Aortic Annuli: The International Multicenter TAVI-SMALL 2 Registry. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, S63-S64.	2.9	0
213	Balloon aortic valvuloplasty review: the revenge during COVID-19 outbreak?. <i>Minerva Cardiology and Angiology</i> , 2022, , .	0.7	0
214	299 – 3-Year results of STEMI patients treated with a pre-specified BVS implantation strategy: BVS SYTEMI strategy-it long term. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
215	90 – Annular size and interaction with trans-catheter aortic valves for the treatment of severe bicuspid aortic valve stenosis: insights from the beat registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
216	680 – Peripheral intravascular lithotripsy of ILEO-femoral arteries to facilitate transfemoral TAVI: a multicentric prospective registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0